AP2015008625A0 - Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases - Google Patents

Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases

Info

Publication number: AP2015008625A0
Authority: AP; ARIPO
Prior art keywords: heterocycle; treatment; methods; viral diseases; tetracyclic compounds
Prior art date: 2013-01-16

Application number

AP2015008625A

Other languages

English (en)

Inventor

shuai Zan

Tao Ji

Wei Wei

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-01-16

Filing date

2013-12-31

Publication date

2015-07-31

2013-12-31 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2015-07-31 Publication of AP2015008625A0 publication Critical patent/AP2015008625A0/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AP2015008625A 2013-01-16 2013-12-31 Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases AP2015008625A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/CN2013/000038 WO2014110687A1 (en)	2013-01-16	2013-01-16	Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
PCT/CN2013/001676 WO2014110705A1 (en)	2013-01-16	2013-12-31	Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases

Publications (1)

Publication Number	Publication Date
AP2015008625A0 true AP2015008625A0 (en)	2015-07-31

Family

ID=51208906

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2015008625A AP2015008625A0 (en)	2013-01-16	2013-12-31	Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases

Country Status (26)

Country	Link
US (1)	US9555038B2 (xx)
EP (1)	EP2945952B1 (xx)
JP (3)	JP6093451B2 (xx)
KR (1)	KR101748974B1 (xx)
CN (1)	CN105073755B (xx)
AP (1)	AP2015008625A0 (xx)
AR (1)	AR094496A1 (xx)
AU (1)	AU2013374112B2 (xx)
BR (1)	BR112015016325A2 (xx)
CA (1)	CA2898049C (xx)
CL (1)	CL2015001971A1 (xx)
CR (1)	CR20150378A (xx)
DO (1)	DOP2015000169A (xx)
EA (1)	EA030554B1 (xx)
EC (1)	ECSP15035530A (xx)
HK (1)	HK1211290A1 (xx)
IL (1)	IL239832A0 (xx)
MA (1)	MA38315B1 (xx)
MD (1)	MD20150075A2 (xx)
MX (1)	MX356203B (xx)
PE (1)	PE20151892A1 (xx)
PH (1)	PH12015501560A1 (xx)
SG (1)	SG11201505536RA (xx)
TN (1)	TN2015000293A1 (xx)
TW (1)	TW201441231A (xx)
WO (2)	WO2014110687A1 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014110687A1 (en) *	2013-01-16	2014-07-24	Merck Sharp & Dohme Corp.	Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
US10457690B2 (en)	2015-06-04	2019-10-29	Merck Sharp & Dohme Corp.	Process for preparing substituted tetracyclic heterocycle compounds
US20180228828A1 (en) *	2015-08-04	2018-08-16	Merck Sharp & Dohme Corp.	Fixed-dose combinations of antiviral compounds
US20180228826A1 (en) *	2015-08-04	2018-08-16	Merck Sharp & Dohme Corp.	Fixed-dose combinations of antiviral compounds
US20190002480A1 (en) *	2015-12-21	2019-01-03	Merck Sharp & Dohme Corp.	Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases
WO2017181383A1 (en)	2016-04-21	2017-10-26	Merck Sharp & Dohme Corp.	Hepatitis c virus inhibitors
WO2017219808A1 (zh) *	2016-06-21	2017-12-28	浙江柏拉阿图医药科技有限公司	丙型肝炎病毒抑制剂及应用
WO2018032468A1 (en) *	2016-08-18	2018-02-22	Merck Sharp & Dohme Corp.	Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2018032467A1 (en) *	2016-08-18	2018-02-22	Merck Sharp & Dohme Corp.	Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases
CN109206396B (zh) *	2017-07-05	2023-03-28	上海迪赛诺化学制药有限公司	2-c-甲基-4,5-o-(1-甲基乙烯基)-d-阿拉伯糖酸乙酯的制备方法
CN109232612A (zh) *	2017-07-11	2019-01-18	周龙兴	抑制丙肝病毒的化合物、药物组合物及其用途
US20210361663A1 (en) *	2018-10-26	2021-11-25	Merck Sharp & Dohme Corp.	Formulations of Antiviral Compounds
JP2024525164A (ja) *	2021-06-17	2024-07-10	アテアファーマシューティカルズ，インコーポレイテッド	有利な抗ｈｃｖ併用療法
WO2022266497A1 (en) *	2021-06-17	2022-12-22	Atea Pharmaceuticals, Inc.	Advantageous anti-hcv combination therapy
WO2024259085A2 (en) *	2023-06-14	2024-12-19	Alexion Pharmaceuticals, Inc.	Methods for the synthesis of complement factor d inhibitors and intermediates thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3927630B2 (ja)	1996-09-27	2007-06-13	エーザイ・アール・アンド・ディー・マネジメント株式会社	ウイルス感染症の予防・治療剤
CN1474815A (zh)	2000-09-20	2004-02-11	Ĭ��ר��ɷ��޹�˾	4-氨基-喹唑啉
WO2005005442A1 (en)	2003-07-10	2005-01-20	Paradigm Therapeutics Ltd.	Silicon compounds and their use
US20070049593A1 (en)	2004-02-24	2007-03-01	Japan Tobacco Inc.	Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
PT1719773E (pt)	2004-02-24	2009-06-03	Japan Tobacco Inc	Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
WO2007084413A2 (en)	2004-07-14	2007-07-26	Ptc Therapeutics, Inc.	Methods for treating hepatitis c
US7153848B2 (en)	2004-08-09	2006-12-26	Bristol-Myers Squibb Company	Inhibitors of HCV replication
US7662809B2 (en)	2004-10-26	2010-02-16	Istituto Di Richerche Di Biologia Molecolare P Angeletti Spa	Tetracyclic indole derivatives as antiviral agents
GB2438802A (en)	2005-02-28	2007-12-05	Univ Rockefeller	Structure of the hepatitis C virus NS5A protein
US7994360B2 (en)	2005-05-16	2011-08-09	Xtl Biopharmaceuticals Ltd.	Benzofuran compounds
US20110104109A1 (en)	2005-07-13	2011-05-05	Frank Bennett	Tetracyclic indole derivatives and their use for treating or preventing viral infections
PL1910338T3 (pl)	2005-07-14	2011-02-28	Irm Llc	Związki heterotetracykliczne jako mimetyki TPO
US7473784B2 (en)	2005-08-01	2009-01-06	Bristol-Myers Squibb Company	Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
FR2894963A1 (fr)	2005-12-16	2007-06-22	Inst Nat Sante Rech Med	Nouveaux composes interagissant avec pea-15
US7745636B2 (en)	2006-08-11	2010-06-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7642251B2 (en)	2007-08-09	2010-01-05	Bristol-Myers Squibb Company	Compounds for the treatment of hepatitis C
US20110130361A1 (en)	2007-08-09	2011-06-02	Jonathan Grimm	Silicon derivatives as histone deacetylase inhibitors
US20090176778A1 (en)	2007-08-10	2009-07-09	Franz Ulrich Schmitz	Certain nitrogen containing bicyclic chemical entities for treating viral infections
AU2008350334B2 (en)	2008-02-13	2013-10-17	Bristol-Myers Squibb Company	Imidazolyl biphenyl imidazoles as hepatitis C virus inhibitors
US7704992B2 (en)	2008-02-13	2010-04-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
PL2310095T3 (pl)	2008-07-22	2013-03-29	Msd Italia Srl	Makrocykliczne związki chinoksaliny jako inhibitory proteazy NS3 HCV
JP5655568B2 (ja)	2008-10-09	2015-01-21	コニカミノルタ株式会社	有機光電変換素子、太陽電池及び光センサアレイ
US8729077B2 (en)	2008-11-28	2014-05-20	Glaxosmithkline Llc	Anti-viral compounds, compositions, and methods of use
HK1203929A1 (en)	2008-12-03	2015-11-06	普雷西迪奥制药公司	Inhibitors of hcv ns5a
US8563513B2 (en)	2009-03-27	2013-10-22	Van Andel Research Institute	Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
CA2755658A1 (en)	2009-03-27	2010-09-30	Presidio Pharmaceuticals, Inc.	Fused ring inhibitors of hepatitis c
PL2410844T3 (pl) *	2009-03-27	2016-08-31	Merck Sharp & Dohme	Inhibitory replikacji wirusa zapalenia wątroby typu c
AU2010253790A1 (en)	2009-05-29	2011-12-15	Merck Sharp & Dohme Corp.	Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C
US8221737B2 (en)	2009-06-16	2012-07-17	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US20130156731A1 (en)	2009-12-22	2013-06-20	Kevin X. Chen	Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
AR080676A1 (es)	2010-03-09	2012-05-02	Schering Corp	Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
MX2013003634A (es) *	2010-09-29	2013-05-20	Merck Sharp & Dohme	Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
WO2012040923A1 (en) *	2010-09-29	2012-04-05	Merck Sharp & Dohme Corp.	Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
WO2012041014A1 (en) *	2010-09-29	2012-04-05	Merck Sharp & Dohme Corp.	Tetracyclic indole derivatives for treating hepatitis c virus infection
WO2014110688A1 (en) *	2013-01-16	2014-07-24	Merck Sharp & Dohme Corp.	Thiophene- sub stitued tetracyclic compounds and methods of use thereof for the treatment of viral diseases
WO2014110687A1 (en) *	2013-01-16	2014-07-24	Merck Sharp & Dohme Corp.	Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases

2013
- 2013-01-16 WO PCT/CN2013/000038 patent/WO2014110687A1/en not_active Ceased
- 2013-12-31 EP EP13871363.1A patent/EP2945952B1/en active Active
- 2013-12-31 MA MA38315A patent/MA38315B1/fr unknown
- 2013-12-31 SG SG11201505536RA patent/SG11201505536RA/en unknown
- 2013-12-31 WO PCT/CN2013/001676 patent/WO2014110705A1/en not_active Ceased
- 2013-12-31 BR BR112015016325A patent/BR112015016325A2/pt not_active Application Discontinuation
- 2013-12-31 MD MDA20150075A patent/MD20150075A2/ro not_active Application Discontinuation
- 2013-12-31 PE PE2015001352A patent/PE20151892A1/es not_active Application Discontinuation
- 2013-12-31 CA CA2898049A patent/CA2898049C/en not_active Expired - Fee Related
- 2013-12-31 EA EA201591328A patent/EA030554B1/ru not_active IP Right Cessation
- 2013-12-31 MX MX2015009225A patent/MX356203B/es active IP Right Grant
- 2013-12-31 AP AP2015008625A patent/AP2015008625A0/xx unknown
- 2013-12-31 KR KR1020157021818A patent/KR101748974B1/ko not_active Expired - Fee Related
- 2013-12-31 US US14/761,256 patent/US9555038B2/en active Active
- 2013-12-31 CN CN201380074735.2A patent/CN105073755B/zh not_active Expired - Fee Related
- 2013-12-31 JP JP2015551946A patent/JP6093451B2/ja not_active Expired - Fee Related
- 2013-12-31 HK HK15112117.6A patent/HK1211290A1/xx unknown
- 2013-12-31 AU AU2013374112A patent/AU2013374112B2/en not_active Ceased
2014
- 2014-01-16 AR ARP140100153A patent/AR094496A1/es unknown
- 2014-01-16 TW TW103101674A patent/TW201441231A/zh unknown
2015
- 2015-06-29 TN TNP2015000293A patent/TN2015000293A1/fr unknown
- 2015-07-08 IL IL239832A patent/IL239832A0/en unknown
- 2015-07-13 CL CL2015001971A patent/CL2015001971A1/es unknown
- 2015-07-13 PH PH12015501560A patent/PH12015501560A1/en unknown
- 2015-07-16 DO DO2015000169A patent/DOP2015000169A/es unknown
- 2015-07-16 CR CR20150378A patent/CR20150378A/es unknown
- 2015-08-17 EC ECIEPI201535530A patent/ECSP15035530A/es unknown
2016
- 2016-11-07 JP JP2016217169A patent/JP6148779B2/ja not_active Expired - Fee Related
- 2016-11-18 JP JP2016225137A patent/JP6417380B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
TW201441231A (zh)	2014-11-01
KR20150104630A (ko)	2015-09-15
JP6148779B2 (ja)	2017-06-14
BR112015016325A2 (pt)	2017-08-22
PH12015501560A1 (en)	2015-09-21
EP2945952A1 (en)	2015-11-25
MA38315A1 (fr)	2017-02-28
JP6417380B2 (ja)	2018-11-07
ECSP15035530A (es)	2017-08-31
CA2898049C (en)	2018-04-17
PE20151892A1 (es)	2015-12-24
JP2017075158A (ja)	2017-04-20
JP6093451B2 (ja)	2017-03-08
CR20150378A (es)	2015-12-09
WO2014110705A1 (en)	2014-07-24
EP2945952A4 (en)	2016-07-20
EA201591328A1 (ru)	2015-11-30
WO2014110705A9 (en)	2015-03-05
CL2015001971A1 (es)	2015-10-23
US20150335648A1 (en)	2015-11-26
MX356203B (es)	2018-05-18
EP2945952B1 (en)	2019-08-28
DOP2015000169A (es)	2015-12-31
CA2898049A1 (en)	2014-07-24
HK1211290A1 (en)	2016-05-20
CN105073755A (zh)	2015-11-18
AU2013374112A1 (en)	2015-07-16
AR094496A1 (es)	2015-08-05
IL239832A0 (en)	2015-08-31
JP2016510321A (ja)	2016-04-07
KR101748974B1 (ko)	2017-06-19
MX2015009225A (es)	2015-10-15
SG11201505536RA (en)	2015-08-28
JP2017095450A (ja)	2017-06-01
WO2014110687A1 (en)	2014-07-24
AU2013374112B2 (en)	2016-11-17
CN105073755B (zh)	2017-08-18
EA030554B1 (ru)	2018-08-31
TN2015000293A1 (en)	2016-10-03
US9555038B2 (en)	2017-01-31
MD20150075A2 (ro)	2016-02-29
MA38315B1 (fr)	2018-05-31

Publication	Publication Date	Title
IL239832A0 (en)	2015-08-31	Tetracyclic compounds transformed with heterocycles and methods of using the compounds to treat viral diseases
IL236700A (en)	2017-02-28	History of alkylpyrimidine for the treatment of viral infections and other diseases
SI2943493T1 (sl)	2017-11-30	Terapevtske spojine za zdravljenje virusnih infekcij
ZA201502238B (en)	2017-01-25	Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
IL240213A (en)	2016-10-31	Sulfamoyl-arylamides and their use as anti-jaundice drugs b
IL241232B (en)	2021-02-28	Cancer treatment agents
IL233499A0 (en)	2014-08-31	History of piperidino-pyrimidine for the treatment of viral infections
EP2968348A4 (en)	2016-11-09	COMPOUNDS FOR THE TREATMENT OF CANCER
EP2958936A4 (en)	2016-11-09	METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE
IL231217A0 (en)	2014-04-30	Tetracyclic heterocyclic compounds and methods of using them in the treatment of viral diseases
SG10201709090UA (en)	2017-12-28	Sobetirome in the treatment of myelination diseases
EP2994460A4 (en)	2017-02-08	Compounds for treatment of angiogenesis-mediated diseases
IL234606B (en)	2021-04-29	Novel methods and composition for treatment of disease
IL243637B (en)	2020-01-30	PPAR-sparing compounds for the treatment of metabolic diseases
EP3083634A4 (en)	2017-06-07	Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
IL242317B (en)	2018-05-31	History of Pyridone for the treatment of viral infections and other diseases
GB201309375D0 (en)	2013-07-10	Medical methods and compounds for medical use
EP2994461A4 (en)	2017-01-25	Methods of treating skin conditions using cyclolignan compounds
IL234796B (en)	2018-02-28	Compounds for the treatment of diseases related to ischemia-reperfusion
EP3013333A4 (en)	2017-01-11	Heterocyclic compounds and methods of use thereof for the treatment of hepatitis c
PL3079684T3 (pl)	2020-06-01	Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
EP3030261A4 (en)	2017-03-22	Methods of treatment of hpv related diseases
GB201309376D0 (en)	2013-07-10	Medical methods and compounds for medical use
GB201321628D0 (en)	2014-01-22	Treatment of disease
GB201309379D0 (en)	2013-07-10	Medical methods and compounds for medical use